Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CM9.0000000000003724 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knockdown of UBD Ameliorates Experimental Rheumatoid Arthritis by Suppressing TLR4/Myd88/NF-κB and P38/MAPK Pathway.
Cell Physiol Biochem
September 2025
Department of General Practice, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China, E-Mail:
Background/aims: Ubiquitin D (UBD), a member of the ubiquitin-like modifier (UBL) family, is significantly overexpressed in various cancers and is positively correlated with tumor progression. However, the role and underlying mechanisms of UBD in rheumatoid arthritis (RA) remain poorly understood. This study aimed to investigate the effects of UBD knockdown on the progression of RA.
View Article and Find Full Text PDFExpanded senescent CD8 T-cells in IMID patients are associated with distinct inflammatory cytokines.
Clin Exp Immunol
September 2025
Rheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA , FHU CARE, Le Kremlin Bicêtre, France.
Introduction: Immunosenescence remodels immune functions and was first described with aging. It is present in 25% of cancer patients but has also been described in patients with Immune-mediated inflammatory diseases (IMIDs). This study aims at quantifying cells exhibiting a phenotype of senescence in CD4+ (T4sen) and CD8+ (T8sen) T cells, analyzing its potential drivers and the effect of anti-TNF treatment in a prospective cohort of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and Sjögren disease (SjD).
View Article and Find Full Text PDFFactors influencing delayed attainment of low disease activity in rheumatoid arthritis patients continuing targeted therapy.
Korean J Intern Med
September 2025
Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Background/aims: To identify factors associated with achieving low disease activity (LDA) after 48 weeks of targeted therapy in patients with rheumatoid arthritis (RA) despite not meeting treat-to-target (T2T) criteria at week 24.
Methods: Data were collected from a multicenter, prospective observational cohort of Korea patients with RA receiving targeted therapy between April 2020 and July 2023. Patients who continued their initial targeted therapy despite not achieving LDA at week 24 were assigned to the LDA and non-LDA groups at week 48.
Bioinformatics, machine learning, and functional validation reveal CCNA2 as a key target of Ammopiptanthus nanus against rheumatoid arthritis.
Int J Biol Macromol
September 2025
School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, 211166, PR China; State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine (Tianjin Institute of Pharmaceutical Research), Tianjin, PR China. Electronic address:
Rheumatoid arthritis (RA) is an autoimmune disease typically characterized by joint pain and dysfunction. Ammopiptanthus nanus (M. Pop.
View Article and Find Full Text PDFEffect of the combination of ion-pairs strategies and permeation enhancers on iguratimod transdermal patch against rheumatoid arthritis.
Eur J Pharm Biopharm
September 2025
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, PR China. Electronic address:
Iguratimod (IGU) is a novel anti-rheumatic drug, which has anti-inflammatory effects, inhibits bone destruction, and promotes bone formation. However, the gastrointestinal side-effects caused by oral tablets of IGU pose a challenge. This study aimed to develop an IGU transdermal patch for Rheumatoid Arthritis (RA) through ion-pair and chemical penetrant strategies to improve the therapeutic efficacy.
View Article and Find Full Text PDF